Temp Ray Patterson, MD | |
1338 Hiland Ave, Suite C, Burley, ID 83318-1561 | |
(208) 878-4197 | |
(208) 878-3638 |
Full Name | Temp Ray Patterson |
---|---|
Gender | Male |
Speciality | Otolaryngology |
Location | 1338 Hiland Ave, Burley, Idaho |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1427153097 | NPI | - | NPPES |
000010001930 | Other | ID | BLUE SHIELD |
70219 | Other | ID | BLUE CROSS |
002796900 | Medicaid | ID |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Y00000X | Otolaryngology | M7021 (Idaho) | Primary |
207Y00000X | Otolaryngology | 13766 (Hawaii) | Secondary |
Mailing Address | Practice Location Address |
---|---|
Temp Ray Patterson, MD 1338 Hiland Ave, Suite C, Burley, ID 83318-1561 Ph: (208) 878-4197 | Temp Ray Patterson, MD 1338 Hiland Ave, Suite C, Burley, ID 83318-1561 Ph: (208) 878-4197 |
News Archive
The Finance Committee resumed its mark-up of a proposal authored by its chairman, Sen. Max Baucus, D-Mont., on Wednesday, with much of the debate gravitating to amendments concerning speed, timing and transparency. Republicans sought to delay the vote, while Democrats argued for a compromise that would bring the committee's deliberations to a swifter conclusion.
Half of the world's human population is infected with the stomach bacteria called Helicobacter pylori, yet it causes disease in only about 10 percent of those infected. Other bacteria living in the stomach may be a key factor in whether or not H. pylori causes disease, according to a new study led by scientists at the University of California, Santa Cruz.
StockPreacher.com announces an investment report featuring ARCA biopharma Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
Healthcare professionals and public health authorities have a central role in discussing vaccination against COVID-19 with their patients.
Accelr8 Technology Corporation announced today that two teams of university research collaborators report new methods for scalable production with the company's patented OptiChem bio-coatings.
› Verified 2 days ago